One example is a trastuzumab biosimilar conjugated to a Toll-like receptor 7/8 (TLR7/8) agonist, designed to activate APCs and potentially overcome therapeutic resistance associated with tumor heterogeneity[80]. This evidence concerns the gene TLR7 and neoplasm.